ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1556335
This article is part of the Research TopicMultidrug Resistant Bacteria: New Therapeutic Approaches for a Challenging ProblemView all 6 articles
Antibacterial and Wound Healing Effects of PEG-Coated Ciprofloxacin-Loaded ZIF-8 Nanozymes Against Ciprofloxacin-Resistant Pseudomonas aeruginosa Taken from Burn Wounds
Provisionally accepted- 1University of Science and Culture, Tehran, Tehran, Iran
- 2Pasteur Institute of Iran (PII), Tehran, Tehran, Iran
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Antimicrobial-resistant (AMR) Pseudomonas aeruginosa (P. aeruginosa) poses a significant challenge in burn wound infections due to its biofilm formation and resistance mechanisms, particularly against ciprofloxacin (CIP). Innovative therapies are urgently needed to improve treatment outcomes for burn patients. This study aimed to develop and evaluate Polyethylene glycol (PEG)-Coated CIP-Loaded zeolitic imidazolate framework-8 (ZIF-8) nanozymes (PEG-ZIF-8-CIP) to enhance antimicrobial efficacy against CIP-resistant P. aeruginosa (CRP) and promote wound healing. Methods: Clinical isolates of CRP were collected from burn patients and confirmed via polymerase chain reaction for the oprL gene. ZIF-8 nanozymes were synthesized, loaded with CIP, and coated with polyethylene glycol to form PEG-ZIF-8-CIP. These nanozymes were characterized using field emission scanning electron microscopy, Fourier-transform infrared spectroscopy, dynamic light scattering, and zeta potential measurements. Their antimicrobial efficacy, biofilm eradication capability, CIP release, and superoxide dismutase-like activity were assessed; Cytotoxicity Assay and wound healing effects were evaluated in a murine burn model infected with CRP. Statistical analyses were performed using ANOVA with Tukey correction in GraphPad Prism (v10.2.1), considering p-values < 0.05 as statistically significant. Results: Among 60 P. aeruginosa isolates, 40 were confirmed as ciprofloxacin-resistant (CRP) and carried the oprL gene. PEG-ZIF-8-CIP nanozymes achieved high drug entrapment efficiency (75%) and strong stability (zeta potential: -31.7 mV), with uniform spherical morphology (~600 nm). Drug release followed a biphasic pattern-50% released in 6 hours, ~90% by 72 hours. The nanozymes showed potent antimicrobial and antioxidant activity, with low MBECs and rapid absorbance reduction. Cytotoxicity was lowest for PEG-ZIF-8-CIP, especially at 24-48 hours. In vivo, PEG-ZIF-8-CIP accelerated burn wound healing, reduced inflammation, promoted fibroblast growth and collagen deposition, and achieved the highest bacterial clearance (up to 84%). Conclusion: PEG-ZIF-8-CIP nanozymes effectively treated ciprofloxacin-resistant P. aeruginosa in burn-wound models by combining strong antimicrobial and anti-biofilm activity with improved wound healing. Encapsulation in ZIF-8 boosted antibiotic potency, while PEGylation enhanced stability, reduced toxicity, and enabled sustained drug release-highlighting their strong potential for combating antimicrobial-resistant wound infections.
Keywords: Pseudomonas aeruginosa, zeolitic imidazolate framework-8 (ZIF-8), PEG-coated nanozymes, CIP-loaded Nanozymes, burn wounds
Received: 06 Jan 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Pahlevani, Beig, Barzi, Shafiei, Chiani, Sohrabi, Sholeh and Nasr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Morvarid Shafiei, Pasteur Institute of Iran (PII), Tehran, Tehran, Iran
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.